1. Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan.
- Author
-
Okami, Suguru, Lecomte, Coralie, Raad, Hanaya, Aguila, Mireia, Mohrova, Zuzana, Takeichi, Makiko, Tsuchiya, Takanori, Ohlmeier, Christoph, Evers, Thomas, and Michel, Alexander
- Subjects
ALDOSTERONE antagonists ,HEART failure patients ,PATIENT compliance ,ANGIOTENSIN-receptor blockers ,OLDER patients ,MINERALOCORTICOID receptors ,ANGIOTENSIN receptors - Abstract
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF drug utilization patterns in 6 months before and after hospitalizations for HF. The adherence to newly initiated HF medications was evaluated based on the proportion of days covered (PDC) and persistence as continuous treatment episodes among new users. The study included 9091 patients hospitalized for HF between January 2016 and September 2019, including 2735 (30.1%) patients who were newly prescribed at least one HF medication after hospitalization. Despite increases in the use of foundational HF therapy (beta-blockers, angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers, or mineralocorticoid receptor antagonists), 35.6% and 7.6% of patients were treated with the HF foundational monotherapy or diuretics alone after hospitalization, respectively. The mean PDC of newly initiated HF medications ranged from 0.57 for thiazide diuretics to 0.77 for sodium-glucose cotransporter-2 inhibitors. Continuous use of HF medications during the first year after initiation was observed in 30–60% of patients. The mean PDC and one-year continuous HF medication use were consistently lower in patients aged ≥ 75 years and in patients with a history of HF hospitalization for all HF medication classes except for tolvaptan and digoxin. Despite the guideline recommendations of HF pharmacotherapy, both treatment and adherence were suboptimal after HF hospitalization, especially in vulnerable populations such as older patients and those with prior HF hospitalizations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF